Protein expression directions
Download
Report
Transcript Protein expression directions
Protein expression directions
•
•
•
•
•
•
•
Synthetic genes
Baculovirus
Multi-leish
Refolding
RINKL plasmid
P. vivax
Superfolders
Alternative approaches to P. fal. protein
expression problems
• Synthetic genes:
– Targets:
• From the “medically important” P. fal. list
• Subset of non-expressors in E. coli
– Blue Heron:
• $3.25/bp x 700 bp x 24 targets = $31,850
• Will receive DNA to be used expression in 2-3 mo
• Baculovirus:
– Targets:
• From the “medically important” P. fal. list
• Subset of insoluble expressors in E. coli
– Abgent:
• Ni-NTA purified recombinant protein for $3850/gene in 7-8 weeks
• 20 targets ≈ $70,000
– Question: can we make SeMet problem in Sf9 cells?
Multi-leish (12 species)
•
•
•
•
•
•
•
•
•
•
•
•
L. major
L. aethiopica
L. donovani
L. tropica
L. amazonensis
L. mexicana
L. guyanensis
L. naiffi
L. braziliensis
L. tarentolae
L. infantum (don’t have yet)
Endotrypanum schaudinni
• Plan experiments for:
– Non-crystallizing soluble
L.mj. proteins
– Insoluble L.mj. proteins
Protein Refolding
(60-70% of L. major targets express as inclusion bodies)
• ProteomTech, Inc.
– Contract for $10,000/refolded protein (1 mg),
or
– Place a PTR instrument in our lab for
$200K/year
• Work on protein refolding on our own
– Need to gain expertise
– Need to dedicate personnel, resources
Dear Fred,
We would be quite agreeable to a trial project to conduct refolding screening on 5 to 20 plasmids.
We would need to work out the exact terms, but we could offer a special price of $10,000 per
protein, and deliver one or more 1 mg samples that appear to be correctly refolded, based on our
internal QC results.
We would also be interested in the placement of a PTR instrument in your laboratories. For
commercial customers we anticipate $500K to $600K annual revenue per instrument (combined
lease/rental plus reagents). For an academic site we would offer the placement for $200K
minimum annually. This could come from monthly rental/lease plus reagents in any combination,
but subject to contractual agreement.
I hope this is sufficient basis for us to begin serious discussions. If so, we would be pleased to
arrange to meet with you and your colleagues in Seattle in the next few weeks.
Sincerely, Don
Donald A. Hawker
Director of Marketing & Business Development
ProteomTech, Inc.
5980 Horton St, Suite 405
Emeryville, CA 94608
Tel: 510-597-9131
Cell: 415-990-4405
Fax: 510-601-6751
www.proteomtech-inc.com